about
Familial hypophosphatemic rickets caused by a large deletion in PHEX geneNationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment.Recent advances in the management of osteoporosisA microRNA regulatory mechanism of osteoblast differentiation.Bone as an endocrine organ.Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer.Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism.Fibroblast growth factor 23 as a phosphotropic hormone and beyond.Anti-fibroblast growth factor 23 antibody therapy.Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced OsteomalaciaFGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism.Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23.Assessment criteria for vitamin D deficiency/insufficiency in Japan - proposal by an expert panel supported by Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral ResearcAssessment criteria for vitamin D deficiency/insufficiency in Japan: proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral ResePhosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells.Functional analysis of mutant FAM20C in Raine syndrome with FGF23-related hypophosphatemia.Phosphate enhances reactive oxygen species production and suppresses osteoblastic differentiation.Oncogenic osteomalacia caused by an occult paranasal sinus tumor.Osteomalacia caused by skull base tumors: report of 2 cases.Tumour-induced osteomalacia.Runx1 and Runx2 cooperate during sternal morphogenesis.The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study.Calcilytic Ameliorates Abnormalities of Mutant Calcium-Sensing Receptor (CaSR) Knock-In Mice Mimicking Autosomal Dominant Hypocalcemia (ADH).Enpp1 is an anti-aging factor that regulates Klotho under phosphate overload conditions.ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors.Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome.Tumor-induced Osteomalacia Caused by a Parotid Tumor.Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review.Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study.Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency.Functional activities of mutant calcium-sensing receptors determine clinical presentations in patients with autosomal dominant hypocalcemia.Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.Pathogenesis and diagnostic criteria for rickets and osteomalacia--proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society.Pathogenesis and diagnostic criteria for rickets and osteomalacia - proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society.Changes in bone metabolic parameters following oral calcium supplementation in an adult patient with vitamin D-dependent rickets type 2A.Development of versatile non-homologous end joining-based knock-in module for genome editing.X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases -Prospect for new treatment.Serum carboxy-terminal telopeptide of type I collagen levels are associated with carotid atherosclerosis in patients with cardiovascular risk factors.Kidney transplantation restored uncoupled bone turnover in end-stage renal disease.
P50
Q28250996-BB46D8CC-E791-463E-B743-99DC769F02ECQ30978233-CA598BCE-4BC6-4685-8329-DBB9A01FBCA3Q33672136-35E9DC44-BE77-4E2A-9D1D-0B85214A95E1Q37469828-C4A44265-7887-4521-A7F5-8C5D0EFA3EECQ37527342-08A04E04-8A60-4277-98B9-B494375504A1Q37616833-4B0A170B-1BC8-4D16-BDEA-29697EBC59CFQ37810380-1669059E-04E4-4A35-8015-09D9315E238CQ37913097-1010A65F-574F-4523-95B4-B3698087AFFEQ38213525-634FD75A-9D34-4519-98A0-BE96E51D1622Q38230408-D8380513-8716-4F28-9ED6-BACE26F55BC9Q38540953-F4158F69-A918-4DFD-B635-E24F27687B4BQ38645925-AB1E28AC-852A-44C1-8426-37669B688EE2Q38779502-E8BE5E68-38DF-4AAF-A4AC-6D1486857FBDQ38791345-286AE12E-1F1F-41D9-94E0-02F22A7AD0D3Q38897244-85D3D164-57D6-43F7-A3C0-1FB1AE9D7BE8Q38975136-57832631-1214-45D6-BEC5-B51551C4F823Q39093888-56A4398D-F389-4763-96B1-CE9D0F6845FAQ39194156-0562ABE4-179C-44D3-8514-1F2FABF6E113Q39261888-3907C215-AE83-4D6E-A415-BE4F3EF1C30CQ39432298-4F2F9899-AD18-453E-A3AE-A8DFDA593E61Q39513286-B8E3CCCD-3AEC-4AAC-BD9F-C3367060CAFDQ39785040-924AAA84-13B6-458A-94E2-4FACEA243DFCQ40946883-C5DDB40B-5720-4497-A0AE-9FA6CC425ADEQ41354101-15C43DE4-A433-42C8-851D-D3847B50FB62Q41630577-8E0415FA-44A4-4F08-AC1D-6FFCC175EEE4Q41929889-DB5C1252-DF43-44F9-8927-13824B1450DEQ42063127-BBBEBCD4-502E-4EF1-BD56-F2667BAD81A1Q42378746-23E5A7E5-5AF5-4E14-A0B2-341385D09A3FQ44419861-86670A51-AB68-4193-91FF-302FB5BC1BD1Q44993064-8F001686-F637-4034-BD76-9E18A6FCEC81Q45233297-19671C15-FAF6-456A-998C-69B0049BDC32Q46044107-AF1EAE1F-5097-4BEB-AB50-2FCA2FDDF433Q46295463-EF9691B6-1DB8-4D5E-BA7D-D77EA1A0426DQ47565483-169877C6-2F09-4DC6-AD1B-4B2873CA8B49Q47566166-6E9678F4-47C0-4949-8701-0F03E361219BQ47807056-B1E2C197-6126-4CDF-BA0A-419E04AF91F2Q49304869-E33F3DC6-50C8-4C05-A179-18C283C55E71Q49577767-A0BD7297-B68F-428F-841F-AC4A1E6A463FQ50931013-91901B0A-D1FD-40D1-8519-D2897517F754Q50933488-E524E3FD-3ADA-4383-9257-81F60BCC8468
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Seiji Fukumoto
@ast
Seiji Fukumoto
@en
Seiji Fukumoto
@es
Seiji Fukumoto
@nl
Seiji Fukumoto
@sl
type
label
Seiji Fukumoto
@ast
Seiji Fukumoto
@en
Seiji Fukumoto
@es
Seiji Fukumoto
@nl
Seiji Fukumoto
@sl
prefLabel
Seiji Fukumoto
@ast
Seiji Fukumoto
@en
Seiji Fukumoto
@es
Seiji Fukumoto
@nl
Seiji Fukumoto
@sl
P1053
B-7853-2015
P106
P21
P31
P3829
P496
0000-0003-3610-3469
P569
2000-01-01T00:00:00Z